Evidence map›Paper›PMID 42115550›Full record

ArticleAnnals of surgical oncology2026

Prognostic Value of Circulating Exosomal DNA in Esophageal Squamous Cell Carcinoma: A Prospective Cohort Study.

Tomoki Nakai, Yuji Kitahata, Hayato Hiraki, Yuki Nakamura, Hideki Motobayashi, Norio Takemoto, Takahiko Hyo, Masatoshi Sato, Toshiyasu Ojima, Keiji Hayata and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tomoki NakaiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Yuji KitahataSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan. yu-kitahata@hyo-med.ac.jp.
Hayato HirakiDivision of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Yuki NakamuraSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Hideki MotobayashiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Norio TakemotoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Takahiko HyoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Masatoshi SatoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Toshiyasu OjimaSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Keiji HayataSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Taro GodaSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Junya KitadaniSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Shinta TominagaSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Shinya HayamiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Atsushi MiyamotoSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Hiroki YamauePancreatic Cancer Center, Department of Hepatobiliary and Pancreatic Surgery, Shonan Kamakura General Hospital, Kanagawa, Japan.
Takeshi IwayaDepartment of Clinical Oncology, Iwate Medical University School of Medicine, Yahaba, Japan.
Satoshi NishizukaDivision of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
Manabu KawaiSecond Department of Surgery, Wakayama Medical University, Wakayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReliable biomarkers for prognostication and recurrence surveillance in esophageal squamous cell carcinoma (ESCC) remain limited. The authors therefore investigated the potential clinical utility of exosomal DNA, which has emerged as a promising component of liquid biopsy.

methodsThis study screened 54 patients with ESCC. After exclusions, 210 blood samples from 21 patients underwent mutation-specific droplet digital polymerase chain reaction assays of plasma exosomal DNA (exoDNA) and circulating tumor DNA (ctDNA) before and after treatment. Kaplan-Meier and receiver operating characteristic analyses were performed to examine associations with overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), and recurrence.

resultsPretreatment exoDNA positivity was significantly associated with shorter DSS (p = 0.035) and shorter RFS (p = 0.048). Post-treatment exoDNA positivity was significantly associated with shorter OS (p = 0.0008), DSS (p = 0.0001), and RFS (p = 0.0001). Post-treatment ctDNA positivity was associated with shorter DSS (p = 0.038).

conclusionsIn ESCC, exoDNA demonstrated prognostic and predictive value, supporting its potential role as a complementary biomarker for postoperative surveillance.

Indexed as

Biomarkers, TumorCirculating Tumor DNAEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExosomesNeoplasm Recurrence, LocalAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesSurvival RateBiomarkers, TumorCirculating Tumor DNABiomarkerCirculating tumor DNAEsophageal squamous cell carcinomaExosomal DNARecurrence prediction

Identifiers

PMID42115550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.